MX2017016519A - Biomarcadores para composiciones de nanoparticulas. - Google Patents
Biomarcadores para composiciones de nanoparticulas.Info
- Publication number
- MX2017016519A MX2017016519A MX2017016519A MX2017016519A MX2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A MX 2017016519 A MX2017016519 A MX 2017016519A
- Authority
- MX
- Mexico
- Prior art keywords
- biomarkers
- nanoparticle compositions
- compositions
- mtor
- limo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physics & Mathematics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562186309P | 2015-06-29 | 2015-06-29 | |
| PCT/US2016/040196 WO2017004264A1 (en) | 2015-06-29 | 2016-06-29 | Biomarkers for nanoparticle compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017016519A true MX2017016519A (es) | 2018-08-16 |
Family
ID=57609078
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017016519A MX2017016519A (es) | 2015-06-29 | 2016-06-29 | Biomarcadores para composiciones de nanoparticulas. |
| MX2023013010A MX2023013010A (es) | 2015-06-29 | 2017-12-15 | Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023013010A MX2023013010A (es) | 2015-06-29 | 2017-12-15 | Composiciones con nanoparticulas que comprenden sirolimus y albumina para usarse en el tratamiento de cancer relacionado con una aberracion activante de m-tor. |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20180177771A1 (enExample) |
| EP (1) | EP3313381A4 (enExample) |
| JP (4) | JP2018527308A (enExample) |
| KR (2) | KR20240144442A (enExample) |
| AU (3) | AU2016285727B9 (enExample) |
| CA (1) | CA2990703C (enExample) |
| HK (1) | HK1254398A1 (enExample) |
| IL (2) | IL312318A (enExample) |
| MX (2) | MX2017016519A (enExample) |
| WO (1) | WO2017004264A1 (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5933893B2 (ja) | 2006-12-14 | 2016-06-15 | アブラクシス バイオサイエンス, エルエルシー | ホルモン受容体状態に基づいてタキサンを含むナノ粒子用いる乳癌治療法 |
| ME03596B (me) | 2009-04-15 | 2020-07-20 | Abraxis Bioscience Llc | Kompozicije nanočesтica bez priona i postupci povezani sa njima |
| CA2794147A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Use of a composition comprising nanoparticles comprising a taxane and an albumin to improve uptake of chemotherapeutics by tumors and for treating a cancer that is highly fibrotic and/or has a dense stroma |
| KR101970342B1 (ko) | 2011-04-28 | 2019-04-18 | 아브락시스 바이오사이언스, 엘엘씨 | 나노입자 조성물의 혈관내 전달 및 그의 용도 |
| EP3560486A1 (en) | 2011-12-14 | 2019-10-30 | Abraxis BioScience, LLC | Use of polymeric excipients for lyophilization or freezing of particles |
| US9511046B2 (en) | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| CA2903454A1 (en) | 2013-03-12 | 2014-10-02 | Abraxis Bioscience, Llc | Methods of treating lung cancer |
| EP2968191B1 (en) | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| US10705070B1 (en) | 2015-03-05 | 2020-07-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug |
| US10527604B1 (en) | 2015-03-05 | 2020-01-07 | Abraxis Bioscience, Llc | Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel |
| EA036790B1 (ru) | 2015-06-29 | 2020-12-22 | АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи | Способ лечения злокачественной пекомы |
| WO2019140257A1 (en) * | 2018-01-11 | 2019-07-18 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for characterizing and treating prostate cancer |
| EP3768268A4 (en) * | 2018-03-20 | 2022-02-23 | Abraxis BioScience, LLC | METHOD OF TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS BY ADMINISTRATION OF NANOPARTICLES OF AN MTOR INHIBITOR AND AN ALBUMINE |
| KR20210024471A (ko) * | 2018-05-22 | 2021-03-05 | 아브락시스 바이오사이언스, 엘엘씨 | 폐고혈압을 치료하기 위한 방법 및 조성물 |
| CN111187834B (zh) * | 2019-01-08 | 2021-01-22 | 中国科学院上海营养与健康研究所 | 胃肠道间质瘤的靶点depdc5及其在诊断和治疗中的应用 |
| CN120267635A (zh) * | 2019-03-19 | 2025-07-08 | 阿布拉科斯生物科学有限公司 | 皮下施用包含mTOR抑制剂和白蛋白的纳米颗粒以治疗疾病 |
| EP4051241A4 (en) | 2019-10-28 | 2023-12-06 | Abraxis BioScience, LLC | PHARMACEUTICAL COMPOSITIONS OF ALBUMIN AND RAPAMYCIN |
| MX2022005715A (es) * | 2019-11-11 | 2022-09-19 | Abraxis Bioscience Llc | Biomarcadores para composiciones de nanoparticulas. |
| AU2021358768A1 (en) * | 2020-10-06 | 2023-05-18 | The Regents Of The University Of Colorado, A Body Corporate | Subject-specific treatments for venetoclax-resistant acute myeloid leukemia |
| WO2022186673A1 (ko) * | 2021-03-05 | 2022-09-09 | 전남대학교산학협력단 | 차세대 염기서열분석 기반 표적유전자 rna 염기서열 분석 패널 및 분석알고리즘 |
| WO2024215799A1 (en) * | 2023-04-11 | 2024-10-17 | Leapfrog Bio, Inc. | Pi3k inhibitors for the treatment of cancer |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3201293A1 (en) * | 2007-03-07 | 2008-09-12 | Abraxis Bioscience, Llc | Nanoparticle comprising rapamycin and albumin as anticancer agent |
| WO2011153009A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| KR20190002733A (ko) * | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| EP2968191B1 (en) * | 2013-03-14 | 2021-06-16 | Abraxis BioScience, LLC | Methods of treating bladder cancer |
| EP2971122B1 (en) * | 2013-03-15 | 2020-08-26 | Memorial Sloan Kettering Cancer Center | Biomarkers for response to rapamycin analogs |
| US20180153863A1 (en) * | 2015-06-29 | 2018-06-07 | Abraxis Bioscience, Llc | Methods of treating solid tumors using nanoparticle mtor inhibitor combination therapy |
-
2016
- 2016-06-29 HK HK18113475.7A patent/HK1254398A1/zh unknown
- 2016-06-29 WO PCT/US2016/040196 patent/WO2017004264A1/en not_active Ceased
- 2016-06-29 KR KR1020247031052A patent/KR20240144442A/ko not_active Ceased
- 2016-06-29 JP JP2017568138A patent/JP2018527308A/ja active Pending
- 2016-06-29 US US15/738,090 patent/US20180177771A1/en not_active Abandoned
- 2016-06-29 EP EP16818726.8A patent/EP3313381A4/en active Pending
- 2016-06-29 KR KR1020187002292A patent/KR102708679B1/ko active Active
- 2016-06-29 MX MX2017016519A patent/MX2017016519A/es unknown
- 2016-06-29 AU AU2016285727A patent/AU2016285727B9/en active Active
- 2016-06-29 IL IL312318A patent/IL312318A/en unknown
- 2016-06-29 CA CA2990703A patent/CA2990703C/en active Active
- 2016-06-29 IL IL256326A patent/IL256326B2/en unknown
-
2017
- 2017-12-15 MX MX2023013010A patent/MX2023013010A/es unknown
-
2021
- 2021-06-25 JP JP2021105535A patent/JP2021169457A/ja active Pending
- 2021-12-20 AU AU2021290200A patent/AU2021290200B2/en active Active
-
2022
- 2022-08-11 US US17/886,329 patent/US20230080409A1/en not_active Abandoned
-
2023
- 2023-02-01 JP JP2023013778A patent/JP2023071656A/ja active Pending
-
2024
- 2024-07-05 AU AU2024204661A patent/AU2024204661A1/en active Pending
-
2025
- 2025-01-15 US US19/022,821 patent/US20250152563A1/en active Pending
- 2025-02-21 JP JP2025026646A patent/JP2025097987A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL256326B1 (en) | 2024-05-01 |
| IL312318A (en) | 2024-06-01 |
| IL256326B2 (en) | 2024-09-01 |
| US20250152563A1 (en) | 2025-05-15 |
| CA2990703C (en) | 2024-04-30 |
| KR20240144442A (ko) | 2024-10-02 |
| CA2990703A1 (en) | 2017-01-05 |
| EP3313381A4 (en) | 2019-02-27 |
| US20230080409A1 (en) | 2023-03-16 |
| WO2017004264A1 (en) | 2017-01-05 |
| KR102708679B1 (ko) | 2024-09-24 |
| AU2024204661A1 (en) | 2024-07-25 |
| AU2016285727B9 (en) | 2021-09-30 |
| MX2023013010A (es) | 2023-11-15 |
| IL256326A (en) | 2018-02-28 |
| AU2016285727A1 (en) | 2018-02-01 |
| HK1254398A1 (zh) | 2019-07-19 |
| US20180177771A1 (en) | 2018-06-28 |
| JP2018527308A (ja) | 2018-09-20 |
| KR20180019230A (ko) | 2018-02-23 |
| AU2021290200B2 (en) | 2024-05-02 |
| EP3313381A1 (en) | 2018-05-02 |
| JP2023071656A (ja) | 2023-05-23 |
| AU2021290200A1 (en) | 2022-01-20 |
| AU2016285727B2 (en) | 2021-09-23 |
| JP2025097987A (ja) | 2025-07-01 |
| JP2021169457A (ja) | 2021-10-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017016519A (es) | Biomarcadores para composiciones de nanoparticulas. | |
| CY1124926T1 (el) | Νανοσωματιδια που περιλαμβανουν σιρολιμους και μια αλβουμινη για χρηση στη θεραπεια ογκων απο επιθηλιοειδη κυτταρα | |
| CY1124215T1 (el) | Μκ2 αναστολεις και χρησεις αυτων | |
| MX378934B (es) | Composición de nanopartículas para usarse en el tratamiento de cáncer de vejiga | |
| MX2015008888A (es) | Metodo para tratar el cancer basado en el nivel de un transportador de nucleosido. | |
| CO2018009275A2 (es) | Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub) | |
| MX2019009361A (es) | Composiciones y metodos para el tratamiento de hemoglobinopatias. | |
| HK1217292A1 (zh) | 基於k- ras的突变状态治疗癌症的方法 | |
| MX2020001550A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| MX369863B (es) | Ciertas entidades quimicas, composiciones y metodos. | |
| CO2018008846A2 (es) | Derivados de carboxamida útiles como inhibidores de rsk | |
| CR20160363A (es) | Heteroarilos y usos de estos | |
| MX2018011992A (es) | Compuestos de aminopurina sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| MX2015015738A (es) | Derivados del bipirazol como inhibidores de janus cinasa (jak). | |
| MX385315B (es) | Composiciones y metodos para inhibir actividad de arginasa. | |
| CR20120528A (es) | Métodos para tratar el cáncer | |
| CL2016003422A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX389962B (es) | Metodos para tratar trastornos mitocondriales y metabolicos. | |
| CL2016003423A1 (es) | Inhibidores de demetilasa-1 específico de lisina | |
| MX2017004600A (es) | Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos. | |
| CO2017011778A2 (es) | Un inhibidor de la actividad del csf-1r y composiciones farmaceuticas que lo comprenden | |
| HK1250944A1 (zh) | 用於治疗癌症的方法 | |
| ECSP14027694A (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
| BR112018013928A2 (pt) | composições terapêuticas e métodos para tratamento da hepatite b | |
| CY1123408T1 (el) | Φαρμακευτικες συνθεσεις και χρηση των αυτων |